AU Patent

AU2024266715A1 — GIP/GLP1 agonist compositions

Assigned to Eli Lilly and Co · Expires 2024-12-19 · 1y expired

What this patent protects

A composition of tirzepatide, comprising an agent selected from NaCl and propylene glycol; and dibasic sodium phosphate is provided.

USPTO Abstract

A composition of tirzepatide, comprising an agent selected from NaCl and propylene glycol; and dibasic sodium phosphate is provided.

Drugs covered by this patent

Mounjaro (TIRZEPATIDE) · Eli Lilly

Patent Metadata

Patent number: AU2024266715A1
Jurisdiction: AU
Classification: —
Expires: 2024-12-19
Drug substance claim: No
Drug product claim: No
Assignee: Eli Lilly and Co
Source: FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.